pharma · Ulcerative Colitis · Multiple Myeloma
AbbVie Deutschland GmbH
AbbVie Deutschland GmbH & Co. KG
AbbVie Deutschland GmbH clinical programs — 20 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Wiesbaden, DE
- Founded
- 2018
- Employees
- 101
- Programs
- 102
- Drugs
- 119
- Patents
- 23
AbbVie Deutschland GmbH projects
20 ClinicalTrials.gov programs sponsored by AbbVie Deutschland GmbH.
AbbVie Deutschland GmbH has 20 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Livmoniplimab, Budigalimab
AbbVie Deutschland GmbH & Co. KG
Locally Advanced or Metastatic Solid Tumors, Solid Tumors
1 trial -
M15-531
AbbVie Deutschland GmbH & Co. KG
Myelodysplastic Syndromes (MDS)
1 trial -
M16-573
AbbVie Deutschland GmbH & Co. KG
Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer
1 trial -
M19-753
AbbVie Deutschland GmbH & Co. KG
Myelofibrosis, Myeloproliferative Neoplasms
1 trial -
M20-258
AbbVie Deutschland GmbH & Co. KG
Multiple Myeloma
1 trial -
M21-404
AbbVie Deutschland GmbH & Co. KG
Advanced solid tumors including (but not limited to), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastric/gastroesophageal junction adenocarcinoma (GEA), colorectal cancer (CRC), and renal cell carcinoma (RCC)
1 trial -
M22-716
AbbVie Deutschland GmbH & Co. KG
Follicular lymphoma (FL), Chronic lymphocytic leukemia (CLL), Diffuse large b-cell lymphoma (DLBCL), B-cell malignancies
1 trial -
M22-947
AbbVie Deutschland GmbH & Co. KG
Relapsed/Refractory Multiple Myeloma
1 trial -
M23-001
AbbVie Deutschland GmbH & Co. KG
Relapsed or Refractory Multiple Myeloma (R/R MM)
1 trial -
M23-385
AbbVie Deutschland GmbH & Co. KG
Advanced solid tumors
1 trial -
M23-647
AbbVie Deutschland GmbH & Co. KG
Select B-Cell malignancies.
1 trial -
M24-291
AbbVie Deutschland GmbH & Co. KG
Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
1 trial -
M24-427
AbbVie Deutschland GmbH & Co. KG
locally advanced or metastatic solid tumors
1 trial -
M24-742
AbbVie Deutschland GmbH & Co. KG
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
1 trial -
M24-893
AbbVie Deutschland GmbH & Co. KG
Non-Hodgkin's Lymphoma
1 trial -
M25-292
AbbVie Deutschland GmbH & Co. KG
Squamous-Cell Non-Small Cell Lung Cancer, Hepatocellular Cancer
1 trial -
M25-433
AbbVie Deutschland GmbH & Co. KG
Systemic Lupus Erythematosus, Sjogren's disease
1 trial -
Mass Balance Study of [14C] ABBV-932 in Healthy Male Volunteers
AbbVie Deutschland GmbH & Co. KG
Healthy Volunteers
1 trial -
PIVEKIMAB SUNIRINE
AbbVie Deutschland GmbH & Co. KG
Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia
1 trial -
TNB383B.0001/M22-466
AbbVie Deutschland GmbH & Co. KG
Relapsed or refractory multiple myeloma
1 trial
Frequently asked questions
How many clinical projects does AbbVie Deutschland GmbH have?
20 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.